Biomay Distributes Lentivirus Starting Plasmids Off-the-Shelf

Press release Vienna, Austria (March 3^rd, 2025) Lentivirus starting plasmids are Biomay’s most recent off-the-shelf offering, as the company today announced. The set of pre-manufactured lentiviral plasmids are designated for the manufacture of recombinant lentiviral gene transfer vectors.

The offered DNA plasmids are immediately available in “RUO” (research use only) quality, whereas GMP-grade lentiviral plasmids will be offered in a few months. Biomay’s lentivirus catalog plasmids are distributed via Biomay’s webshop.

The following lentiviral starting plasmids are now available in RUO quality:

• • • An envelope plasmid providing the envelope glycoprotein derived from the vesicular stomatitis virus glycoprotein G / VSV-G (for broad target cell tropism)
    • A packaging plasmid coding for the structural proteins (gag) and functional enzymes (pol)
    • A packaging plasmid coding for the gene expression regulators rev

Together with a fourth plasmid – an individual and target-specific transgene plasmid – Biomay’s set of lentiviral plasmids represents today’s preferred „3^rd generation“ approach. This four-plasmid system ensures a high safety standard within the lentiviral vector system.
Today, lentiviral gene transfer vectors are of enormous importance for numerous cell and gene therapies. In particular, T-cells transduced by lentiviral vectors to express chimeric antigen receptors (CAR-T) is state-of-the-art in the clinical development of numerous cancer therapies.
Biomay’s recent lentivirus offering perfectly complements last year’s launch of numerous adeno-associated virus / AAV plasmids. Later on this year, Biomay will make more lentiviral plasmids available, such as reporter and transgene backbone vectors.

Clients will benefit from Biomay’s lentiviral offering:

1. Off-the-shelf availability. Biomay’s plasmids are immediately available at various aliquot sizes for immediate purchase, accelerating clients’ project timelines.
2. Excellent plasmid quality: Each plasmid undergoes rigorous quality control testing to ensure purity, stability, performance and batch-to-batch consistency.
3. Seamless GMP compliance: Biomay’s GMP certification guarantees stringent regulatory requirements, paving the way for smooth and time-saving clinical development.

About Biomay

Biomay AG is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins in E. coli has been Biomay’s business focus yet from its beginning. Today, Biomay offers cGMP services for manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA and therapeutic recombinant proteins. Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical, commercial). The company’s scope of services comprises process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle / LNP formulation and aseptic filling. Biomay’s facilities are inspected by the US FDA.

Contact:

Dr. Angela Neubauer, Senior Vice President Client Business; request@biomay.com
Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria; www.biomay.com

Learn more about Biomay’s Lentiviral catalog plasmids: Lentiviral Plasmids
More details on Biomay‘s custom made plasmid services: Plasmid DNA